Drug Type Interferons, Biosimilar |
Synonyms Recombinant Human Interferon α2b, 干扰素α2b生物类似药(长春生物制品), Changshengfukang + [1] |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 2000), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Condylomata Acuminata | China | 01 Jan 2000 | |
Hairy Cell Leukemia | China | 01 Jan 2000 | |
Hepatitis | China | 01 Jan 2000 | |
Hepatitis, Chronic | China | 01 Jan 2000 | |
Philadelphia chromosome positive chronic myelogenous leukemia | China | 01 Jan 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute viral hepatitis | Phase 1 | China | 10 Jul 2019 | |
Chronic viral hepatitis | Phase 1 | China | 10 Jul 2019 | |
Herpes Zoster | Phase 1 | China | 10 Jul 2019 |